Moleculin Biotech, Inc. Gains 125.7%
Wed, Apr 08, 2020 at 05:30 PM
Moleculin Biotech, Inc. (MBRX:NASDAQ) jumped higher at $1.27, representing a gain of 125.7%. On Tue 07 Apr 20, MBRX:NASDAQ hit a New 2-Week Intraday Low of $0.52. The stock appeared on our News Catalysts scanner on Wed 08 Apr 20 at 05:14 PM in the 'BIOTECH' category. From Tue 24 Mar 20, the stock recorded 30.00% Up Days and 27.27% Green Days
The stock spiked on Thu 19 Mar 20 at $0.81 with a volume of 14M+, and its share price has been moving sideways in recent weeks.
About Moleculin Biotech, Inc. (MBRX:NASDAQ)
Moleculin Biotech Inc is a preclinical stage pharmaceutical company. The company is engaged in the development of anti-cancer drug candidates. Its drug development technologies include liposomal Annamycin, WP1122 and WP1066.
Top 10 Gainers:
- BIOLASE, Inc. (BIOL:NASDAQ), 249.57%
- Moleculin Biotech, Inc. (MBRX:NASDAQ), 125.7%
- Ellington Financial Inc. (EFC:NYSE), 74.71%
- Moxian, Inc. (MOXC:NASDAQ), 64.15%
- Intelsat S.A. (I:NYSE), 57.14%
- Exantas Capital Corp. (XAN:NYSE), 51.78%
- Capricor Therapeutics, Inc. (CAPR:NASDAQ), 50.85%
- Ellington Residential Mortgage REIT (EARN:NYSE), 50.37%
- New York Mortgage Trust, Inc. (NYMT:NASDAQ), 49.25%
- Forestar Group Inc. (FOR:NYSE), 47.06%